The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Official Title: Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Study ID: NCT00884845
Brief Summary: Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib, in patients with advanced malignant solid tumors.
Detailed Description: Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib, determine the preliminary pharmacokinetics (PK) of the combination, evaluate the preliminary PK/pharmacodynamic correlation, evaluate the preliminary antitumor activity, perform a preliminary pharmacogenomic (PGx) study to explore molecular predictors of response to ErbB receptor antagonists and PM02734 in patient with advanced malignant solid tumors.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Montefiore Medical Center, New York, New York, United States
Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
Intituto Universitario Dexeus, Barcelona, , Spain
Name: Roman Pérez-Soler, M.D.
Affiliation: Montefiore Medical Center (NY - USA)
Role: PRINCIPAL_INVESTIGATOR
Name: Rafael Rosell, M.D.
Affiliation: Hospital Universitario Germans Trias i Pujol (Badalona - Spain)
Role: PRINCIPAL_INVESTIGATOR
Name: Mauricio Cuello, M.D.
Affiliation: Instituto Universitario Dexeus (Barcelona - Spain)
Role: PRINCIPAL_INVESTIGATOR